Aziz Yasri

Dr. Aziz Yasri


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2014 in mAbs
Verified
Journal Article
Open access
BFBénédicte FAUVEL
Bénédicte FAUVEL
AYAziz Yasri
Aziz Yasri
Approximately 30 therapeutic monoclonal antibodies have already been approved for cancers and inflammatory diseases, and monoclonal antibodies continue to be one of the fastest growing classes of t...

1 November 2014 in Chemistry & Biology
Verified
Journal Article
Closed access
AMAbdellah Messoussi
Abdellah Messoussi
CFClémence Feneyrolles
Clémence Feneyrolles
ABAurélie Bros
Aurélie Bros
ADArthur Deroide
Arthur Deroide
BDBénédicte Daydé
Bénédicte Daydé
AYAziz Yasri
Aziz Yasri

10 October 2014 in Molecules
Verified
Journal Article
Open access
PDF file
AMAbdellah Messoussi
Abdellah Messoussi
LPLucile Peyronnet
Lucile Peyronnet
CFClémence Feneyrolles
Clémence Feneyrolles
GCGwénaël Chevé
Gwénaël Chevé
Khalid BougrinKhalid Bougrin
Khalid Bougrin
AYAziz Yasri
Aziz Yasri
Structural elucidation of the active (DFG-Asp in) and inactive (DFG-Asp out) states of the TAM family of receptor tyrosine kinases is required for future development of TAM inhibitors as drugs. Herein we report a computational study on each of the three TAM members Tyro-3, Axl and Mer. DFG-Asp in and DFG-Asp out homology models of each one were built based on the X-ray structure of c-Met kinase, an enzyme with a closely related sequence. Structural validation and in silico screening enabled identification of critical amino acids for ligand binding within the active site of each DFG-Asp in and DFG-Asp out model. The position and nature of amino acids that differ among Tyro-3, Axl and Mer, and the potential role of these residues in the design of selective TAM ligands, are discussed.